AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms RAINBOWFISH
- Sponsors Roche
- 14 Dec 2018 Status changed from planning to recruiting.
- 09 Oct 2018 New trial record
- 03 Oct 2018 According to Roche media release, study will be expected by early 2019.